From VLA's ASX release about the Lepu investment (in the about Lepu Medical paragraph):
"Moreover, Lepu Medical has pipeline products in the diabetes and cancer immunotherapy realms with PD-1 and PD-L1 checkpoint inhibitors in
clinical trials in China."
So it looks like Lepu's motivation is pretty clear - differentiate themselves in the Chinese market with the best combination before their bigger and faster to market PD-1 and PD-L1 competitors. Which means they will want to kick off combination trials quickly. Trust MM can get them to pay for those trials (in addition to the equity investment they have already made).
VLA Price at posting:
68.5¢ Sentiment: Hold Disclosure: Held
